Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Montana: - Billings Clinic Cancer Center — Billings, Montana
- Benefis Sletten Cancer Institute — Great Falls, Montana
- Hi-Line Sletten Cancer Center — Havre, Montana
Phase 3 Recruiting Academic/Other
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tum…
Sponsor: NRG Oncology
NCT ID: NCT04134260
Sites in Montana: - Billings Clinic Cancer Center — Billings, Montana
- Benefis Sletten Cancer Institute — Great Falls, Montana
Phase 3 Recruiting Network
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in Montana: - Billings Clinic Cancer Center — Billings, Montana
- Bozeman Health Deaconess Hospital — Bozeman, Montana
- Benefis Sletten Cancer Institute — Great Falls, Montana
- Great Falls Clinic — Great Falls, Montana
- Hi-Line Sletten Cancer Center — Havre, Montana
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Montana: - Billings Clinic Cancer Center — Billings, Montana
- Bozeman Deaconess Hospital — Bozeman, Montana
- Saint James Community Hospital and Cancer Treatment Center — Butte, Montana
- Benefis Healthcare- Sletten Cancer Institute — Great Falls, Montana
- Kalispell Regional Medical Center — Kalispell, Montana
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Montana: - Community Hospital of Anaconda — Anaconda, Montana
- Billings Clinic Cancer Center — Billings, Montana
- Bozeman Health Deaconess Hospital — Bozeman, Montana
- Benefis Sletten Cancer Institute — Great Falls, Montana
- Great Falls Clinic — Great Falls, Montana
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Montana: - Community Hospital of Anaconda — Anaconda, Montana
- Billings Clinic Cancer Center — Billings, Montana
- Saint Vincent Frontier Cancer Center — Billings, Montana
- Bozeman Health Deaconess Hospital — Bozeman, Montana
- Benefis Sletten Cancer Institute — Great Falls, Montana
Phase 3 Recruiting Network
This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body i…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06470243
Sites in Montana: - Community Hospital of Anaconda — Anaconda, Montana
- Billings Clinic Cancer Center — Billings, Montana
- Bozeman Health Deaconess Hospital — Bozeman, Montana
- Benefis Sletten Cancer Institute — Great Falls, Montana
- Great Falls Clinic — Great Falls, Montana
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Sponsor: AstraZeneca
NCT ID: NCT06120491
Sites in Montana: - Research Site — Billings, Montana
- Research Site — Bozeman, Montana
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in Montana: - St. Vincent Frontier Cancer Center-Research ( Site 0037) — Billings, Montana
Phase 3 Recruiting Network
This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06235697
Sites in Montana: - Billings Clinic Cancer Center — Billings, Montana
Phase 2 Recruiting Academic/Other
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632977
Sites in Montana: - Billings Clinic Cancer Center — Billings, Montana
Phase 2 Recruiting Academic/Other
This study investigates the efficacy of a telehealth exercise program designed specifically for rural cancer survivors with cancer-related fatigue (CRF). Small dried blood samples and measures of physical function will be collected through…
Sponsor: University of Colorado, Denver
NCT ID: NCT07001241
Sites in Montana: - University of Montana — Missoula, Montana
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Montana: - Community Hospital of Anaconda — Anaconda, Montana
- Billings Clinic Cancer Center — Billings, Montana
- Bozeman Health Deaconess Hospital — Bozeman, Montana
- Benefis Sletten Cancer Institute — Great Falls, Montana
- Great Falls Clinic — Great Falls, Montana
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Montana: - Massive Bio SYNERGY-AI site — Billings, Montana
Recruiting Academic/Other
This study investigates how well radium-223 works in treating patients with castration-resistant prostate cancer than has spread to the bones (bone metastases). Prostate cancer is the most common cancer in men and the second leading cause …
Sponsor: University of Washington
NCT ID: NCT04489719
Sites in Montana: - Bozeman Health Deaconess Hospital — Bozeman, Montana